( LEXINGTON Mass.--(BUSINESS WIRE)--May ...)Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting,Health

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that survival and sub-population data from the Phase 2b clinical trial in metastatic melanoma of the Company's lead oncology drug candidate, STA-4783, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on Tuesday, June 5, 2007. In this double-blind, randomized, multi-center trial, patients treated with STA-4783 in combination with paclitaxel were compared with patients treated with paclitaxel alone. All patients had stage IV metastatic melanoma.

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, controlled, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

The schedule and meeting places for the presentation, together with the abstract numbers, are listed below:

Poster Presentations

Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Presentation: 17

Abstract No. 8528

"Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-47
'"/>

Page: 1 2 3
Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Pharmaceuticals to Host Conference Call Today
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
9. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
10. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
11. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago